Related Experiment Video
Updated: Jun 13, 2025
Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
Published on: August 21, 2021
Sclerostin Antibody-Loaded Dense Collagen Hydrogels Promote Critical-Size Bone Defect Repair
Ludovic Sicard1,2, Sophie Maillard1, Daline Mbita Akoa3
1Université Paris Cité, Institut des Maladies Musculo-Squelettiques, Orofacial Pathologies, Imaging and Biotherapies Laboratory URP2496 and FHU-DDS-Net, Dental School, and Plateforme d'Imagerie du Vivant (PIV), 92120 Montrouge, France.
Local delivery of anti-sclerostin antibodies from dense collagen hydrogels effectively repairs bone defects. This approach enhances bone regeneration and reduces antibody dosage, offering a promising, cost-effective therapy for extensive bone loss.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Orthopedic Research
Background:
- Extensive bone loss presents a significant clinical challenge.
- Current research focuses on combining biomaterials, biomolecules, and stem cells for bone repair.
- Systemic administration of anti-sclerostin antibodies has shown potential in enhancing bone repair.
Purpose of the Study:
- To evaluate the efficacy of locally delivered anti-sclerostin antibodies from dense collagen hydrogels (DCHs) for craniofacial bone repair.
- To assess if encapsulated antibodies can locally inhibit sclerostin and promote bone regeneration.
- To compare the effectiveness of local antibody delivery with systemic administration and stem cell incorporation.
Main Methods:
- Antibodies against sclerostin were loaded into DCHs.
- In vitro studies assessed hydrogel structure and cell viability (murine dental pulp stem cells - mDPSCs).
- In vivo studies implanted antibody-loaded DCHs into mouse calvarial critical-size bone defects.
Main Results:
- Antibody loading did not alter DCH structure or mDPSC viability.
- Antibody-loaded DCHs demonstrated bone repair capabilities comparable to acellular DCHs with systemic antibody injections.
- The addition of mDPSCs did not provide additional bone repair benefits.
Conclusions:
- Local delivery of anti-sclerostin antibodies from acellular DCH scaffolds is a highly effective strategy for bone repair.
- This method significantly reduces the required antibody amount compared to systemic delivery, lowering procedure costs.
- The proposed strategy represents a promising therapeutic approach for repairing large bone defects.
